<DOC>
	<DOC>NCT02921035</DOC>
	<brief_summary>This is an open label, non randomized, uncontrolled, multicenter, single arm observational study. In this study, the enrolled subjects will be treated with Rebif human serum albumin (HSA)-free formulation (with or without RebiSmart) 44 microgram (mcg), subcutaneous (sc), thrice in a week (tiw) for 24 months.</brief_summary>
	<brief_title>Non-interventional Study to Assess Adherence to Treatment for Patients With Relapsing Multiple Sclerosis</brief_title>
	<detailed_description />
	<mesh_term>Sclerosis</mesh_term>
	<mesh_term>Multiple Sclerosis</mesh_term>
	<mesh_term>Interferons</mesh_term>
	<mesh_term>Interferon-beta</mesh_term>
	<mesh_term>Interferon beta-1a</mesh_term>
	<criteria>Male and female subjects aged more than or equal to (&gt;=) 18 years and less than or equal to (&lt;=) 60 years at the time of Rebif introduction Subjects diagnosed with RMS according to the revised McDonald criteria (2010) Treatment naïve or subjects on other DMDs who will switch to Rebif. Subjects will receive 1st Rebif 44 mcg dose after signing informed consent Subjects willing and able to provide signed informed consent. Have any contraindications to treatment with IFN beta1a sc according to European summary of product characteristics (EU SPC)/prescribed information Subjects participating in other clinical studies/trials Any female subject of childbearing potential who is not on contraceptives Subjects refusal to participate in the study.</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>60 Years</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>Relapsing Multiple Sclerosis</keyword>
	<keyword>Interferon beta-1a</keyword>
	<keyword>Rebif®</keyword>
	<keyword>Morisky Medication Adherence Scale</keyword>
</DOC>